C31G

Drug Profile

C31G

Alternative Names: C31G vaginal gel; Glyminox gel; PRE 106; SAVVY

Latest Information Update: 01 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biosyn
  • Developer Biosyn; Louisiana State University Health Sciences Center; National Institute of Child Health and Human Development
  • Class Amines; Antibacterials; Antivirals; Small molecules; Spermicidal contraceptives; Unsaturated fatty acids
  • Mechanism of Action Membrane lipid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pregnancy

Highest Development Phases

  • Preclinical Dendritic keratitis
  • Suspended Pregnancy
  • Discontinued Chlamydial infections; Gonorrhoea; HIV infections

Most Recent Events

  • 09 Sep 2013 Preclinical trials in Dendritic keratitis in USA (Ophthalmic)
  • 09 Sep 2013 Pharmacodynamics and adverse events data from preclinical studies in Dendritic keratitis released by Adamis Pharmaceuticals Corporation
  • 08 Dec 2010 C31G is available for licensing as of 08 Dec 2010. http://www.adamispharmaceuticals.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top